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ABSTRACT
MicroRNAs (miRNAs) are small (19–24nt), nonpro-
tein-coding nucleic acids that regulate specific
‘target’ gene products via hybridization to mRNA
transcripts, resulting in translational blockade or
transcript degradation. Although miRNAs have
been implicated in numerous developmental and
adult diseases, their specific impact on biological
pathways and cellular phenotypes, in addition to
miRNA gene promoter regulation, remain largely
unknown. To improve and facilitate research of
miRNA functions and regulation, we have developed
MMIA (microRNA and mRNA integrated analysis), a
versatile and user-friendly web server. By incorpor-
ating three commonly used and accurate miRNA
prediction algorithms, TargetScan, PITA and
PicTar, MMIA integrates miRNA and mRNA expres-
sion data with predicted miRNA target information
for analyzing miRNA-associated phenotypes and
biological functions by gene set analysis, in addition
to analysis of miRNA primary transcript gene
promoters. To assign biological relevance to the
integrated miRNA/mRNA profiles, MMIA uses
exhaustive human genome coverage, including
classification into various disease-associated
genes as well as conventional canonical pathways
and Gene Ontology. In summary, this novel web
server (cancer.informatics.indiana.edu/mmia) will
provide life science researchers with a valuable
tool for the study of the biological (and pathological)
causes and effects of the expression of this class of
interesting protein regulators.
INTRODUCTION
MicroRNAs (miRNAs) are a class of endogenous (non-
protein-coding), 19–24nt single-stranded RNAs that
derive from a stem–loop precursor to regulate gene expres-
sion by binding primarily to the 30-UTR of speciﬁc ‘target’
mRNAs, resulting in the disruption of mRNA stability
and/or translation (1). Due to their posttranscriptional
regulatory eﬀects, miRNAs act to ‘ﬁne tune’ the levels of
proteins involved in numerous biological processes,
including embryogenesis, organogenesis, tissue homeosta-
sis, immune system function and cell cycle control (2–4).
The biosynthesis and maturation of miRNAs is quite
distinct from that of small inhibitory RNAs (siRNAs),
involving processing of a several kb primary RNA tran-
script to the 70–80 base stem loop pre-miRNA. The stem–
loop precursor is then exported from the nucleus and
further processed by the endoribonuclease Dicer to pro-
duce the mature, single-stranded molecule that is incorpo-
rated into the RNA-induced silencing complex (RISC)
and possesses a 6nt ‘seed’ sequence (nucleotide positions
2–7) that primarily targets complementary regions within
the 30-untranslated regions of mRNA transcripts (5). As a
general rule, perfect miRNA seed-to-target complemen-
tarity results in degradation of the mRNA target tran-
script, but can also block protein synthesis at the level
of translation (5).
Due to their integral roles in tissue generation andhome-
ostasis, disruptions in miRNA expression have now been
linked to numerous pathologies, including those related to
neuronal development (6), cardiac function (7), immune
system (4,8), neurodegeneration (e.g. Alzheimer’s disease)
(9–11), skin (e.g. psoriasis) (12) and numerous malignan-
cies (2,4,8,13). The extensive association of miRNAs with
human cancer has led to the acronym ‘oncomirs’, with the
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number of oncomirs being oncogenic (13). In support of
tumor suppressor function, one study found that over 52%
of annotated miRNA genes reside in so-called ‘fragile sites’
of cancer-associated chromosomal instability (14).
Another microarray study of 217 miRNAs in 334 primary
human tumors revealed miRNA expression clusters dis-
tinct to 20 diﬀerent malignancies (40). Consequently, due
to the widespread association of speciﬁc miRNAs with
malignant disease, these gene regulatory molecules hold
promise as diagnostic, prognostic or treatment-response
biomarkers, in addition to representing possible therapeu-
tic targets.
In comparison to annotated protein-coding genes, very
little is currently known regarding regulation of primary
miRNA (pri-miRNA) transcripts. A handful of studies
have examined epigenetic regulation of pri-miRNA
genes (15–17), while Drosphila embryonic miRNAs were
found to be regulated in a spatial manner (18). A more
recent study utilized a transcriptionally permissive histone
‘mark’ to locate possible pri-miRNA promoters (19).
However, although pri-miRNAs are transcribed by
RNA polymerase II, the detailed transcriptional regula-
tion (e.g. binding of transcription factors, coactivators,
corepressors) remains unknown for the vast majority of
miRNA genes. Additionally, despite the extensive role of
miRNAs in development, homeostasis and numerous dis-
ease states, relatively little is known regarding mature
miRNA regulation of speciﬁc biological pathways and cel-
lular phenotypes (2). As the biological eﬀects of miRNAs
are due to their modulation of target protein expression,
accurate miRNA target prediction is essential to any study
of miRNA function. While databases of experimentally
validated miRNA targets, including MiRecords (20) and
TarBase (21), are becoming more extensive, bioinformatic
algorithms remain the principal means of predicting tar-
gets of speciﬁc miRNAs. These algorithms take into
account numerous parameters that inﬂuence miRNA/
target interactions, including seed match complementar-
ity, 30-UTR seed match context, seed match conservation,
favorability of free energy binding, AU content and bind-
ing site accessibility (1). Currently, three of the most
widely used, and predictively accurate algorithms are
TargetScan, PITA and PicTar, although more recent pre-
diction methods, such as Miranda and mirWIP, are also
increasingly being used (1).
As previously noted, perfect seed-to-target comple-
mentarity is most prominently associated with transcript
degradation (as opposed to translational blockage).
Consequently, target prediction algorithms requiring
stringent seed matching can be used to determine likely
miRNA target regulation by identifying (e.g. by microar-
ray or high-throughput sequencing) inversely correlated
expression of miRNAs and their predicted target mRNA
transcripts. Moreover, by subjecting those speciﬁc inver-
sely regulated miRNA-target transcripts to standard gene
ontology and pathway analyses, determinations can be
made regarding the likely biological and phenotypic
eﬀects of the misexpressed miRNAs.
While such an integrated approach (miRNA target
ontology/pathway analysis) is fairly straightforward, it
requires the sequential use of multiple demanding and
time-consuming computational analyses. One study sub-
jected publically available miRNA datasets, from ﬁve spe-
ciﬁc cancer types, to miRgate Gene Ontology (GO)
analysis to categorize GO groups likely impacted by
those cancer-dysregulated miRNAs, while also identifying
miRNA target proteins aﬀected by anticancer drugs (22).
Other miRNA prediction algorithms/databases have
now incorporated experimentally validated miRNA:
target interactions. A previously developed database,
miRGator, can classify miRNA targets (as determined
by the miRanda, PicTar and TargetScanS algorithms)
according to GO terms and disease associations (23).
Similarly, miRNAMap 2.0 incorporates both publically
available miRNA and mRNA expression databases, and
provides a list of tissue-speciﬁc miRNAs, but does not
include pathway or GO analyses (24), while conversely,
a Microsoft Excel-based program compares experimental
gene expression data to publically available miR target
predictions (25). While some analysis tools, such as
miRNApath (26) and DIANA-miRPath (diana.cslab.
ece.ntua.gr/pathways/) support pathway analyses, for
most currently available miRNA databases/target pre-
dictors, the gene expression data or predicted miRNA
targets must be separately subjected to biological classiﬁ-
cation tools, such as Gene Set Analysis (GSA) (27).
Likewise, unlike extensive databases of gene expression-
based disease ‘signatures’ (28–30), we are aware of only
one such algorithm for associating miRNA expression
proﬁles with speciﬁc diseases (31).
Despite their noteworthy objective of miRNA target
classiﬁcation, several limitations remain for these pre-
viously developed tools. First, most of these utilize only
mRNA microarray (or publicly available) gene expression
proﬁles, while others are limited to providing the predicted
targets of only one miRNA per analysis session. Currently
available tools for analyzing multiple miRNAs cannot
analyze mRNA expression data using GSA. Second, cur-
rent miRNA analysis tools are restricted to supporting
pathways, GO, or diseases only individually, while most
mRNA analysis tools can support all three of these in one
combined algorithm. Also, to our knowledge, there is
currently no comprehensive tool that integrates both
miRNA and mRNA expression data, in combination
with pri-miRNA promoter transcription factor-binding
site analysis, within a single web interface. Finally,
miRNA gene set analysis based on direct relationship
between a biological term and its miRNA gene list is not
currently available (for example, a miRNA gene set ana-
lysis including a transcription factor (TF) term enriched
in pri-miRNA regions and a disease term highly related to
miRNAs based on publications). Since the roles of tran-
scription factors in a miRNA promoter region have been
elucidated in embryonic stem cells (19), miRNA/TF gene
sets have now gained importance. These miRNA gene sets
could be constructed similarly to other mRNA gene sets,
based on either literature or experimental data.
To address these limitations, we have now designed an
integrated miRNA/mRNA-analyzing web server, MMIA
(microRNA and mRNA integrated analysis), that com-
binatorially analyzes both miRNA expression data (or
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a recent method that can also analyze multiple miRNA
genes (32). MMIA thus provides a ‘one-stop’ combined
analysis of the miRNA/mRNA input data for various
gene sets including pathways, GO, cancer, genetic/chemi-
cal perturbation and diseases. We have now compiled
miRNA/TF gene sets and miRNA/disease gene sets for
our additional analysis. In summary, we have implemen-
ted a practical, user-friendly web server for extensive bio-
logical functional analysis of multiple miRNAs. We
believe MMIA will be a valuable tool, in combination
with traditional mRNA GSA tools, for the biomedical
research community.
MATERIALS AND METHODS
Combined analysis of miRNA and mRNA
The MMIA web-server is a novel approach for integrating
miRNA and mRNA expression data, based on our recent
study (32). Although the precise mechanism(s) by which
miRNAs induce mRNA degradation and regulate protein
expression by posttranscriptional silencing have not been
fully elucidated (33,34), perfect miRNA seed:target com-
plementarity is predominantly associated with target
gene destabilization (33). Thus, MMIA compares inverse
expression of mRNAs and miRNAs (e.g. upregulated
miRNAs and downregulation of their predicted target
mRNAs). To use MMIA, the user ﬁrst selects signiﬁcantly
up- or down-regulated miRNAs from ‘group 2’ on the
input data webpage (Supplementary Figure 1). The ﬁrst
dataset (e.g. the control), in our customized ‘SIP’ ﬁle
format (see below and documentation web page), and
any subsequent replicates of that dataset, are automati-
cally assigned to ‘group 1’, while the second (e.g. experi-
mental) dataset (with its replicates) is designated ‘group 2’.
For example, in Step 1 (MMIA web page, Supplementary
Figure 1), if up-regulated miRNAs are selected, MMIA
identiﬁes the signiﬁcantly (using user-deﬁned statistical
cutoﬀ values) up-regulated group 2 miRNAs (as com-
pared to group 1). If, however, a user selects down-
regulated miRNAs, MMIA identiﬁes signiﬁcantly less
expressed miRNAs in group 2. As described in Figure 1,
when upregulated miRNAs are selected, MMIA identiﬁes
all signiﬁcantly down-regulated mRNAs in the mRNA
expression data analysis. The mRNAs common to the
predicted target mRNAs and the down-regulated
mRNAs are then selected, with MMIA determining the
gene intersection by GSA analysis using various pre-
deﬁned gene set databases, including KEGG (35), MIT
MSigDB database v2.5 (36) and G2D (37). GSA diﬀers
from individual gene analysis (IGA) by directly scoring
predeﬁned gene sets for misexpression (27); GSEA, one
type of GSA analysis developed by Subramanian et al.
(36), is a widely used algorithm that utilizes a competitive
statistic (‘score function’) to represent diﬀerentially
expressed genes within a speciﬁc gene set. MMIA also
performs additional analyses, including transcription
factor binding site identiﬁcation within the pri-miRNA
gene promoters of upregulated miRNAs, in addition to
miRNA associations with speciﬁc diseases (31).
Data sources
MMIA utilizes two major gene set databases, one for
mRNA gene sets and the other for miRNA gene sets.
The mRNA gene sets consist of canonical pathways, posi-
tional information, chemical/genetic perturbation, GO,
cancer genes and inherited diseases (35,36). These
mRNA sets come from KEGG (35), MIT MSigDB (36)
and G2D (37). MSigDB has positional gene sets, chemi-
cal/genetic perturbation, canonical pathway gene sets,
cancer gene sets and GO gene sets, while G2D contains
inherited disease gene sets. Our additional miRNA gene
sets are composed of transcription factor binding sites
(genome.ucsc.edu) (38) in annotated pri-miRNA regions
and a disease-related miRNA database, miR2Disease (31).
Each miRNA gene set consists of one biological term
and its corresponding miRNA gene list. The pri-miRNA
regions are deﬁned using a recent annotation method (19),
and the transcription factor-binding site information
was obtained from the UCSC Genome Browser TFBS
Conserved track (38). These binding sites are conserved
using human/mouse/rat multiple species alignments.
MMIA uses three miRNA target prediction algorithms,
TargetScan (39), PicTar (PicTar 4 species conservation,
PicTar 5 species conservation) (40) and PITA (probability
of interaction by target accessibility) (41) that require
stringent miRNA seed:target complementarity (thus
favoring mRNA transcript degradation). We obtained
TargetScan release 4.2 (Apr. 2008) (www.targetscan.org)
and collected conserved sites, while PicTar was down-
loaded from the UCSC Genome Browser human NCBI
Build 35. We obtained PITA (version 6, 31-Aug-08) Sites
catalog (3/15 ﬂank) from genie.weizmann.ac.il/pubs/
mir07/mir07_data.html. PITA identiﬁes initial seeds for
each miRNA 30-UTR binding site and then combines
sites for the same miRNA to obtain a total miRNA:
target interaction score, while also accounting for site
accessibility (41). PicTar searches miRNAs for multiple
alignments to potential orthologous 30-UTR sequences
and subsequently ranks genes by optimal free energies of
binding, while also accounting for synergistic eﬀects of
multiple binding sites of one or more miRNAs and the
number of evolutionarily conserved putative 30-UTR
binding sites (40). TargetScan, currently the most widely
used miR target prediction tool, relies on strict miRNA
seed region (miRNA bases 2–7) complemantarity, but also
considers bases 1 and 8, in addition to the context of the
miRNA-binding site, the proximal AU composition, and
proximity to sites for co-clustered miRNAs (thus enhanc-
ing cooperative action) (42).
For gene expression analysis, Aﬀymetrix chip annota-
tion information (for 10 separate microarray platforms)
was downloaded from the Aﬀymetrix web page (www.
aﬀymetrix.com). A non-Aﬀymetrix platform can also be
selected by ‘custom platforms’ option on the MMIA web
page (Supplementary Figure 1), a feature supporting
diﬀerent probe names, including Ensemble Transcript
(www.ensembl.org), NCBI RefSeq, mRNA/protein and
Entrez Gene (www.ncbi.nlm.nih.gov), Swiss-Prot (www.
ebi.ac.uk/swissprot) and Gene Symbol (www.gene
names.org).
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information in MMIA are stored in a MySQL database,
the gene sets are stored in MIT GSEA GMT and CHIP
ﬁle formats (www.broad.mit.edu/cancer/software/gsea/
wiki/index.php/Data_formats), and the executables were
written in Perl and R. Since the data sources utilize diﬀer-
ent gene annotations, these are converted to the nomen-
clature used in the UCSC Genes (43) annotation system.
WEB SERVER DESCRIPTION
Procedure
Using the MMIA tool is quite straightforward, starting
with the input web page, which is composed of four man-
datory steps and a ﬁfth optional step (Supplementary
Figure 1), while the procedures in MMIA follow the
same order shown in Figure 1. For steps 1 and 3 of the
Figure 1. Overview of the combined analysis of microRNA and mRNA expression data in MMIA, based on our previous published
methodology (32).
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data, respectively. In Step 1, the user submits a miRNA
gene list and is also prompted to select either up- or down-
regulated miRNAs for data analysis. Step 2 provides not
only selection of the desired miRNA target prediction
algorithm (TargetScan, PicTar or PITA) (39–41) but
also allows a combinatorial analysis, based on the inter-
section of two of the algorithms. Step 4 of the web page
allows users to select gene sets for GSA analysis, based
on our recently described method (32). Step 5 provides
optional analyses of examining enriched transcription
factor binding sites within miRNA primary transcript pro-
moter regions, disease associations, and an alternative
miRNA–mRNA combined analysis, using MIT GSEA
software (36).
Input
The miRNA and mRNA expression data input for MMIA
uses a simple tab-delimited data format, followed by
two header lines for the group and dataset descriptions.
We deﬁned the tab-delimited ﬁle format called SIP. Users
divide test datasets into two groups and then specify them
in the ﬁrst header line. The second header line consists of
a descriptive name for each sample column. To provide
further versatility, users can also enter a regulated miRNA
list in the miRNA input ﬁeld (box under ‘Regulated
miRNA list’) on the web page.
Gene/probe identiﬁers in expression data or SIP format
can consist of Ensemble Transcript (www.ensembl.org),
NCBI RefSeq mRNA/protein and Entrez Gene (www.
ncbi.nlm.nih.gov), Swiss-Prot (www.ebi.ac.uk/swissprot),
Gene Symbol and Aﬀymetrix probe sets (www.aﬀymet
rix.com). For non-Aﬀymetrix mRNA expression probe
sets, users should select the ‘Custom’ chip platform
option in Step 3 (Supplementary Figure 1). The input
expression data allows duplicated probe names in both
miRNA and mRNA microarrays. Although the expres-
sion data is linear (not log-2 scale), data values can
easily be converted to antilog 2. When only log fold-
change values and P-values are available (in an EXCEL
sheet format, for example), users can also easily convert
the data into the SIP ﬁle format, as shown in the docu-
mentation web page.
Currently, MMIA supports only two-group compari-
son analysis. MMIA, with the ﬁrst dataset in a SIP ﬁle
assigned to group 1 and the other dataset to group 2. The
ﬁrst data samples in both miRNA and mRNA arrays
belong to the same sample group. In most cases, the ﬁrst
sample (group 1) would correspond to a control group
and the group 2 to an experimental group. The fold-
change notation in MMIA is a median of group 2 samples
over a median of group 1 samples. When the user pastes a
miRNA gene list and uploads mRNA expression data into
MMIA, by default, MMIA assumes that the miRNAs are
down-regulated in group 2.
For expression data, MMIA provides a number of
preprocessing and test options. The preprocessing
options can be used to remove genes with extremely low
or high values, data transformation into log-2 scale, and
standardization of gene expression values from multiple
microarrays, as based on a Bioconductor tutorial (www.
bioconductor.org/workshops/2002/Summer02Course/).
The test options are used to ﬁnd miRNA/mRNA tran-
scripts that are signiﬁcantly diﬀerentially expressed bet-
ween the two groups. When the biclustering option in
the miRNA analysis is used, MMIA generates a cluster
ﬁgure of signiﬁcantly diﬀerentially expressed miRNAs,
with three test options: user-deﬁned fold-change, user-
deﬁned t-test statistics (P-value), or combination of the
two. Users can also use a false discovery rate correction
(44) in t-test statistics.
Output
The output shows not only signiﬁcantly diﬀerentially
expressed miRNAs and their predicted mRNA target
information, but also miRNA-mRNA expression com-
bined analysis based on one-sided Fisher’s exact test for
the selected gene sets. The combined miRNA and mRNA
analysis is performed for the gene sets in terms of the
intersection between signiﬁcantly diﬀerentially expressed
mRNA and predicted target mRNAs by multiple up-/
down-regulated miRNA genes.
An example MMIA output, which consisting of ﬁve
sections, is shown in Supplementary Figure 2. Group
descriptions and sample names, based on miRNA/
mRNA SIP ﬁles provided by the user, are summarized
in the ﬁrst section. The second section lists either up- or
down-regulated miRNAs from miRNA expression data
analysis, selected by the user, and also provides a hierar-
chical clustering ﬁgure for the miRNAs. The third section
is the miRNA gene set analysis. This section describes
TFBSs enriched in primary transcript regions of the
selected miRNAs and diseases associated with the
miRNAs. The fourth section provides a predicted target
mRNA list of the selected miRNAs and also shows
target mRNA expression levels. The main result of the
combined analysis (based on Xin, et al.) (32), is shown
in the ﬁfth section.
CONCLUSION
MMIA is a novel web tool that analyzes both miRNA and
mRNA expression data simultaneously, providing 5782
gene sets encompassing numerous pathways, functions,
cancer genes, chromosomal position and inherited dis-
eases. In addition, MMIA signal transduction, cell cycle,
chromatin remodeling, TF and stemness gene sets also
provide biological implications of miRNA expression.
MMIA also provides miRNA gene sets based on TF bind-
ing sites in pri-miRNA regions and a manually curated
disease/miRNA database, and we will compile more
gene sets in the future, in addition to considering
miRNA translational repression (at the protein level). In
summary, we strongly believe that MMIA will be a highly
informative data analysis tool for the life sciences research
community, and will provide valuable information regard-
ing the role of microRNAs in numerous normal and dis-
ease states.
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